

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies

Biology

LLUCC-BIOSPECIMEN
 LABORATORY - SPECIMEN
 COLLECTION

Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection
 Protocol

[Mark E. Reeves, MD, PhD](#)

Brain

SWOG-NRG-BN001

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
<https://clinicaltrials.gov/ct2/show/NCT02179086>

[Joseph Kang, MD](#)

SWOG-A221101

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma
<https://clinicaltrials.gov/ct2/show/NCT01781468>

[Muhammad Kamal, MD](#)

SWOG-EAF151

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
<https://clinicaltrials.gov/ct2/show/NCT03115333>

[Muhammad Kamal, MD](#)

Breast

NSABP-B51

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
<https://clinicaltrials.gov/ct2/show/NCT01872975>

[Sharon Lum, MD](#)

NSABP-B58

A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer
<https://clinicaltrials.gov/ct2/show/NCT03155997>

[Gayathri Nagaraj, MD](#)

SWOG-A011106

ALternate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
<https://clinicaltrials.gov/ct2/show/NCT01953588>

[Gayathri Nagaraj, MD](#)

SWOG-A011202

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
<https://clinicaltrials.gov/ct2/show/NCT01901094>

[Sharon Lum, MD](#)

SWOG-S1207

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with High-Risk Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
<http://www.clinicaltrials.gov/ct2/show/NCT01674140>

[Gayathri Nagaraj, MD](#)

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies

Breast continued

Investigator Initiated GRASP-CIPN	A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy https://clinicaltrials.gov/ct2/show/NCT03272919	Gayathri Nagaraj, MD
SWOG-S1418-BR006	A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy https://clinicaltrials.gov/ct2/show/NCT02954874	Gayathri Nagaraj, MD

GI

Bowel

SWOG-S1316	Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction https://clinicaltrials.gov/ct2/show/NCT02270450	Maheswari Senthil, MD
------------	--	---------------------------------------

Colon

SWOG-S0820	A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) http://www.clinicaltrials.gov/ct2/show/NCT01349881	Chung-Tsen Hsueh, MD, PhD
------------	--	---

Esophagus

Radiation Medicine	A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer https://clinicaltrials.gov/ct2/show/NCT01684904	Gary Yang, MD
--------------------	---	-------------------------------

Gastric

Investigator Initiated HIPEC	Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer https://clinicaltrials.gov/ct2/show/NCT02672865	Maheswari Senthil, MD
------------------------------	---	---------------------------------------

Liver

Radiation Medicine	Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases https://clinicaltrials.gov/ct2/show/NCT01697371	Gary Yang, MD
--------------------	---	-------------------------------

Pancreas

Radiation Medicine	A phase II trial of gemcitabine and erlotinib (GB) plus proton-chemotherapy (PCT) and capox for locally advanced pancreatic cancer (LAPC) https://clinicaltrials.gov/ct2/show/NCT01683422	Gary Yang, MD
--------------------	--	-------------------------------

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies

GU

Kidney / Urothelial

Urogen-TC-UT-03-P

A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on Ablation of Upper Urinary Tract Urothelial Carcinoma
<https://clinicaltrials.gov/ct2/show/NCT02793128>

[Brian Hu, MD](#)

Prostate

Radiation Medicine

Phase I-II trial of hypofractionated conformal proton beam radiation therapy for favorable-risk prostate Cancer
<https://clinicaltrials.gov/ct2/show/NCT00831623>

[Jerry Slater, MD](#)

Radiation Medicine

Cytogenetic damage as a biomarker of radiation sensitivity in prostate cancer

Marcelo Vazquez , MD, PhD

Testicular

Investigator Initiated-4T-14-1

Phase II Trials of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma with Isolated Retroperitoneal Disease (1-2cm)
<https://clinicaltrials.gov/ct2/show/NCT02537548>

[Brian Hu, MD](#)

GYN

Multiple

Investigator Initiated-Paclitaxel

Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in gynecologic-oncology patients: A prospective, randomized, open-label study
<https://clinicaltrials.gov/ct2/show/NCT03598426>

[Linda Hong, MD](#)

Ovarian

Investigator Initiated HIPEC

Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
<https://clinicaltrials.gov/ct2/show/NCT02672098>

[Mazdak Momeni, MD](#)

Uterus

GOG-0263

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
<https://clinicaltrials.gov/ct2/show/NCT01101451>

[Yevgeniya Ioffe, MD](#)

GOG-0238

A Randomized Trial Of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin In Patients With Pelvic-Only Recurrence Of Carcinoma Of The Uterine Corpus
<https://clinicaltrials.gov/ct2/show/NCT00492778>

[Linda Hong, MD](#)

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies

Lung

SWOG-A151216	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) https://clinicaltrials.gov/ct2/show/NCT02194738	Hamid Mirshahidi, MD
SWOG-A081105	Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) https://clinicaltrials.gov/ct2/show/NCT02194738	Hamid Mirshahidi, MD
SWOG-EA5142	Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers https://clinicaltrials.gov/ct2/show/NCT02595944	Hamid Mirshahidi, MD
SWOG-E4512	A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein https://clinicaltrials.gov/ct2/show/NCT02201992	Hamid Mirshahidi, MD
SWOG-S1400	Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer http://clinicaltrials.gov/ct2/show/NCT02154490	Hamid Mirshahidi, MD
Pfizer-B7461020	An expanded access protocol for Lorlatinib for treatment of patients with advanced non-small cell lung cancer harboring specific molecular alterations https://clinicaltrials.gov/ct2/show/NCT03178071	Hamid Mirshahidi, MD

Lymphoma

SWOG-S1609	Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma https://clinicaltrials.gov/ct2/show/NCT03269669	Muhammad Kamal, MD
SWOG-S1608	Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma https://clinicaltrials.gov/ct2/show/NCT03269669	Muhammad Kamal, MD

Multiple

SWOG-EAY131-MATCH	Molecular Analysis for Therapy Choice (MATCH) https://clinicaltrials.gov/ct2/show/NCT02465060	Gayathri Nagaraj, MD
SWOG-S1609	DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors https://clinicaltrials.gov/ct2/show/NCT02834013	John Wong, MD

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Adult Open Studies

Soft Tissue Sarcoma

SWOG-A091401	Randomized Phase II Study of Nivolumab with or without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma https://clinicaltrials.gov/ct2/show/NCT02500797	Gayathri Nagaraj, MD
Radiation Medicine	A phase II study of preoperative proton therapy in soft tissue sarcomas of the extremities and body wall https://clinicaltrials.gov/ct2/show/NCT01819831	Gary Yang, MD

Registry

Radiation Medicine	Radiation Medicine Patient Registry https://clinicaltrials.gov/ct2/show/NCT02436941	Jerry Slater, MD
--------------------	--	----------------------------------